Candidate genes showing no evidence for association or linkage with Alzheimer's disease using family-based methodologies - PubMed (original) (raw)
. 2000 Dec;35(9-10):1353-61.
doi: 10.1016/s0531-5565(00)00193-5.
D Blacker, A Crystal, K Mullin, D Keeney, J Jones, S Basu, S Yhu, S Guénette, M McInnis, R Go, R Tanzi
Affiliations
- PMID: 11113613
- DOI: 10.1016/s0531-5565(00)00193-5
Candidate genes showing no evidence for association or linkage with Alzheimer's disease using family-based methodologies
L Bertram et al. Exp Gerontol. 2000 Dec.
Abstract
Alzheimer's disease (AD) is a genetically complex and heterogeneous disorder. To date, a large number of candidate genes have been associated with the disease, however none of these findings has been consistently replicated in independent datasets. In this study we report the results of family-based analyses for polymorphisms of five such candidates on chromosomes 2 (interleukin-1beta, IL-1B), 3 (butyrylcholinesterase, BCHE), 11 (cathepsin D, CTSD; Fe65, APBB1) and 12 (lipoprotein receptor-related protein-1, LRP1) that were all suggested to be associated with AD in recent case-control studies. To minimize the possibility of spurious findings due to population admixture, we used a family-based design applying the sibship disequilibrium test (SDT) as well as two-point parametric linkage analyses on families from the National Institute of Mental Health (NIMH) Genetics Initiative. Contrary to the initial reports, none of the polymorphisms that were analyzed showed evidence for association or linkage with AD in our families. Our results suggest that the previously reported associations from case-control studies are either (a) false positive results, e.g. due to type I error or population admixture, (b) smaller than initially proposed, or (c) due to linkage disequilibrium with an as yet unidentified polymorphism nearby.
Similar articles
- Evidence against association of the FE65 gene (APBB1) intron 13 polymorphism in Alzheimer's patients.
Guénette SY, Bertram L, Crystal A, Bakondi B, Hyman BT, Rebeck GW, Tanzi RE, Blacker D. Guénette SY, et al. Neurosci Lett. 2000 Dec 15;296(1):17-20. doi: 10.1016/s0304-3940(00)01607-4. Neurosci Lett. 2000. PMID: 11099823 - No evidence for genetic association or linkage of the cathepsin D (CTSD) exon 2 polymorphism and Alzheimer disease.
Bertram L, Guénette S, Jones J, Keeney D, Mullin K, Crystal A, Basu S, Yhu S, Deng A, Rebeck GW, Hyman BT, Go R, McInnis M, Blacker D, Tanzi R. Bertram L, et al. Ann Neurol. 2001 Jan;49(1):114-6. doi: 10.1002/1531-8249(200101)49:1<114::aid-ana18>3.0.co;2-m. Ann Neurol. 2001. PMID: 11198280 - No association between an intronic biallelic polymorphism of the FE65 gene and Alzheimer's disease.
Papassotiropoulos A, Bagli M, Becker K, Jessen F, Maier W, Rao ML, Ludwig M, Heun R. Papassotiropoulos A, et al. Int J Mol Med. 2000 Nov;6(5):587-9. doi: 10.3892/ijmm.6.5.587. Int J Mol Med. 2000. PMID: 11029529 - Candidate gene association studies in sporadic Alzheimer's disease.
Combarros O, Alvarez-Arcaya A, Sánchez-Guerra M, Infante J, Berciano J. Combarros O, et al. Dement Geriatr Cogn Disord. 2002;14(1):41-54. doi: 10.1159/000058332. Dement Geriatr Cogn Disord. 2002. PMID: 12053131 Review. - The current status of Alzheimer's disease genetics: what do we tell the patients?
Bertram L, Tanzi RE. Bertram L, et al. Pharmacol Res. 2004 Oct;50(4):385-96. doi: 10.1016/j.phrs.2003.11.018. Pharmacol Res. 2004. PMID: 15304236 Review.
Cited by
- Association between LRP1 C766T polymorphism and Alzheimer's disease susceptibility: a meta-analysis.
Wang Y, Liu S, Wang J, Zhang J, Hua Y, Li H, Tan H, Kuai B, Wang B, Sheng S. Wang Y, et al. Sci Rep. 2017 Aug 16;7(1):8435. doi: 10.1038/s41598-017-08335-w. Sci Rep. 2017. PMID: 28814781 Free PMC article. - Genetic polymorphism of interleukin 1β -511C/T and susceptibility to sporadic Alzheimer's disease: a meta-analysis.
Yuan H, Xia Q, Ge P, Wu S. Yuan H, et al. Mol Biol Rep. 2013 Feb;40(2):1827-34. doi: 10.1007/s11033-012-2237-0. Epub 2012 Oct 19. Mol Biol Rep. 2013. PMID: 23079713 - Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities.
Sagare AP, Deane R, Zlokovic BV. Sagare AP, et al. Pharmacol Ther. 2012 Oct;136(1):94-105. doi: 10.1016/j.pharmthera.2012.07.008. Epub 2012 Jul 20. Pharmacol Ther. 2012. PMID: 22820095 Free PMC article. Review. - Cellular basis of Alzheimer's disease.
Bali J, Halima SB, Felmy B, Goodger Z, Zurbriggen S, Rajendran L. Bali J, et al. Ann Indian Acad Neurol. 2010 Dec;13(Suppl 2):S89-93. doi: 10.4103/0972-2327.74251. Ann Indian Acad Neurol. 2010. PMID: 21369424 Free PMC article. - Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brain.
Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA. Zlokovic BV, et al. J Neurochem. 2010 Dec;115(5):1077-89. doi: 10.1111/j.1471-4159.2010.07002.x. Epub 2010 Oct 5. J Neurochem. 2010. PMID: 20854368 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous